Mary‐ellen Taplin
#158,594
Most Influential Person Now
Mary‐ellen Taplin's AcademicInfluence.com Rankings
Mary‐ellen Taplinmedical Degrees
Medical
#3146
World Rank
#3601
Historical Rank
Oncology
#214
World Rank
#222
Historical Rank
Pharmacology
#377
World Rank
#428
Historical Rank
Mary‐ellen Taplinphilosophy Degrees
Philosophy
#9054
World Rank
#12551
Historical Rank
Logic
#6054
World Rank
#7534
Historical Rank
Download Badge
Medical Philosophy
Mary‐ellen Taplin's Degrees
- Doctorate Medicine Harvard University
- PhD Biological Chemistry and Molecular Pharmacology Harvard University
Why Is Mary‐ellen Taplin Influential?
(Suggest an Edit or Addition)Mary‐ellen Taplin's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Increased survival with enzalutamide in prostate cancer after chemotherapy. (2012) (3907)
- Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. (2004) (3631)
- Integrative Clinical Genomics of Advanced Prostate Cancer (2015) (2458)
- Abiraterone in metastatic prostate cancer without previous chemotherapy. (2013) (2446)
- Enzalutamide in metastatic prostate cancer before chemotherapy. (2014) (2357)
- Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. (1995) (1281)
- Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. (2016) (1060)
- Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. (2015) (1059)
- Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study (2010) (1004)
- Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. (2016) (889)
- Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care Options (2017) (683)
- Genomic correlates of clinical outcome in advanced prostate cancer (2019) (647)
- Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. (1999) (623)
- Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. (2007) (586)
- The long tail of oncogenic drivers in prostate cancer (2018) (529)
- Whole exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer (2014) (479)
- Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors (2017) (469)
- Androgen receptor: A key molecule in the progression of prostate cancer to hormone independence (2004) (417)
- Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. (2010) (413)
- Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. (2003) (398)
- Integrative Clinical Genomics of Advanced Prostate Cancer (2015) (383)
- Comparative Studies of the Estrogen Receptors β and α and the Androgen Receptor in Normal Human Prostate Glands, Dysplasia, and in Primary and Metastatic Carcinoma (2001) (378)
- Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. (2006) (290)
- Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part II: Recommended Approaches and Details of Specific Care Options (2018) (287)
- Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. (2001) (287)
- Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. (2014) (262)
- Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. (2020) (260)
- Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). (2014) (254)
- Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma. (2015) (244)
- Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. (1997) (241)
- Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. (2014) (222)
- High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. (1998) (221)
- Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing (2018) (221)
- Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study. (2014) (213)
- Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. (2014) (211)
- Phase II Study of Abiraterone Acetate in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Displaying Bone Flare Discordant with Serologic Response (2011) (210)
- Drug Insight: role of the androgen receptor in the development and progression of prostate cancer (2007) (210)
- Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. (2001) (208)
- American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. (2004) (196)
- Metastatic pattern of bladder cancer: correlation with the characteristics of the primary tumor. (2011) (190)
- Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. (2012) (171)
- SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. (2011) (154)
- Abiraterone Treatment in Castration-Resistant Prostate Cancer Selects for Progesterone Responsive Mutant Androgen Receptors (2014) (150)
- Clinical review 134: The endocrinology of prostate cancer. (2001) (135)
- Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer (2018) (135)
- Redirecting abiraterone metabolism to fine tune prostate cancer anti-androgen therapy (2016) (133)
- Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. (2020) (129)
- Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: Results from the phase III AFFIRM study. (2012) (125)
- Time to prostate‐specific antigen nadir independently predicts overall survival in patients who have metastatic hormone‐sensitive prostate cancer treated with androgen‐deprivation therapy (2009) (121)
- Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment (2018) (114)
- Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer (2008) (114)
- Prostate Cancer–Specific Mortality Across Gleason Scores in Black vs Nonblack Men (2018) (111)
- Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study. (2005) (103)
- A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone‐refractory prostate cancer who are refractory to docetaxel (2008) (98)
- Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer (2020) (94)
- Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. (2006) (90)
- Atypical metastases from prostate cancer: 10-year experience at a single institution. (2012) (89)
- Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. (2008) (85)
- Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC) (2018) (84)
- Phase II Study of Androgen Synthesis Inhibition with Ketoconazole, Hydrocortisone, and Dutasteride in Asymptomatic Castration-Resistant Prostate Cancer (2009) (82)
- Phase II trial of RAD001 and bicalutamide for castration‐resistant prostate cancer (2012) (75)
- Tumor fraction in cell-free DNA as a biomarker in prostate cancer. (2018) (74)
- Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. (2018) (74)
- A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of cancer and leukemia group B Trial 9780. (1999) (73)
- Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide resistant prostate cancer (2017) (72)
- Neoadjuvant Enzalutamide Prior to Prostatectomy (2016) (72)
- Expression of PD-L1 in Hormone-naïve and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide (2017) (70)
- Transcriptional mediators of treatment resistance in lethal prostate cancer (2020) (69)
- Targeted androgen pathway suppression in localized prostate cancer: a pilot study. (2014) (69)
- Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone. (2019) (68)
- Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer (2015) (67)
- A phase II study of mifepristone (RU‐486) in castration‐resistant prostate cancer, with a correlative assessment of androgen‐related hormones (2008) (65)
- Androgen receptor: role and novel therapeutic prospects in prostate cancer (2008) (64)
- Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy (2017) (62)
- Effect of neoadjuvant abiraterone acetate (AA) plus leuprolide acetate (LHRHa) on PSA, pathological complete response (pCR), and near pCR in localized high-risk prostate cancer (LHRPC): Results of a randomized phase II study. (2012) (62)
- Impact of on-study corticosteroid use on efficacy and safety in the phase III AFFIRM study of enzalutamide (ENZA), an androgen receptor inhibitor. (2013) (60)
- The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer. (2015) (56)
- Castration-Resistant Prostate Cancer Bone Metastasis Response Measured by 18F-Fluoride PET After Treatment with Dasatinib and Correlation with Progression-Free Survival: Results from American College of Radiology Imaging Network 6687 (2015) (56)
- Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high‐risk localized prostate cancer (2012) (53)
- Presumptive evidence for Blastocystis hominis as a cause of colitis. (1988) (53)
- Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations. (2018) (51)
- The IMAAGEN Study: Effect of Abiraterone Acetate and Prednisone on Prostate Specific Antigen and Radiographic Disease Progression in Patients with Nonmetastatic Castration Resistant Prostate Cancer (2018) (49)
- Second-Line Hormonal Therapy for Men With Chemotherapy-Naïve, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion. (2017) (48)
- Antitumor activity of MDV3100 in a phase I/II study of castration-resistant prostate cancer (CRPC). (2009) (47)
- Results of a Randomized Phase II Trial of Intense Androgen Deprivation Therapy Prior to Radical Prostatectomy in Men with High-Risk Localized Prostate Cancer. (2021) (47)
- Functional analysis of single cells identifies a rare subset of circulating tumor cells with malignant traits. (2014) (45)
- Response to docetaxel/carboplatin‐based chemotherapy as first‐ and second‐line therapy in patients with metastatic hormone‐refractory prostate cancer (2008) (42)
- Rationale for and Review of Neoadjuvant Therapy Prior to Radical Prostatectomy for Patients with High-Risk Prostate Cancer (2013) (42)
- Systematic Review of Systemic Therapies and Therapeutic Combinations with Local Treatments for High-risk Localized Prostate Cancer. (2019) (41)
- Primary, secondary, and quality-of-life endpoint results from the phase III AFFIRM study of MDV3100, an androgen receptor signaling inhibitor. (2012) (41)
- Radium‐223 Use in Clinical Practice and Variables Associated With Completion of Therapy (2017) (41)
- Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update. (2021) (41)
- Development, validation and application of a stable isotope dilution liquid chromatography electrospray ionization/selected reaction monitoring/mass spectrometry (SID-LC/ESI/SRM/MS) method for quantification of keto-androgens in human serum (2013) (41)
- Phase I clinical trial of galeterone (TOK-001), a multifunctional antiandrogen and CYP17 inhibitor in castration resistant prostate cancer (CRPC). (2012) (40)
- Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non–Muscle-Invasive Bladder Cancer (2020) (40)
- ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer (2016) (40)
- Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade (2018) (39)
- Long-term Safety and Antitumor Activity in the Phase 1-2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer. (2015) (39)
- Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry (2019) (38)
- Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC). (2019) (37)
- Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. (2019) (37)
- Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. (2022) (35)
- A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer. (2015) (35)
- Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer (2018) (35)
- Muscadine Grape Skin Extract (MPX) in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial (2017) (35)
- Urothelial Cancers of the Upper Urinary Tract: Metastatic Pattern and Its Correlation With Tumor Histopathology and Location (2011) (34)
- Downregulation of Dipeptidyl Peptidase 4 Accelerates Progression to Castration-Resistant Prostate Cancer. (2018) (34)
- Novel agents and new therapeutics in castration-resistant prostate cancer (2011) (34)
- Vitamin B12 levels and age. (1986) (31)
- Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. (2018) (30)
- Androgen Deprivation Therapy Is Associated With Prolongation of QTc Interval in Men With Prostate Cancer (2018) (29)
- Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer. (2020) (29)
- Monitoring the serological proteome: the latest modality in prostate cancer detection. (2004) (29)
- Androgen Receptor Modulation Optimized for Response-Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7-expressing Metastatic Castration-resistant Prostate Cancer. (2019) (29)
- Imaging, procedural and clinical variables associated with tumor yield on bone biopsy in metastatic castration-resistant prostate cancer (2014) (29)
- A Randomized Phase II Trial of Short-Course Androgen Deprivation Therapy With or Without Bevacizumab for Patients With Recurrent Prostate Cancer After Definitive Local Therapy. (2016) (28)
- Phase II multicenter study of chemotherapy (chemo)-naive castration-resistant prostate cancer (CRPC) not exposed to ketoconazole (keto), treated with abiraterone acetate (AA) plus prednisone. (2016) (28)
- Association of Tissue Abiraterone Levels and SLCO Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer (2017) (27)
- A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer (2016) (27)
- Abstract CT-07: ARMOR1: Safety of galeterone (TOK-001) in a Phase 1 clinical trial in chemotherapy naïve patients with castration resistant prostate cancer (CRPC) (2012) (27)
- Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. (2018) (27)
- Effects of Androgen Deprivation Therapy on Pain Perception, Quality of Life, and Depression in Men With Prostate Cancer. (2017) (26)
- Predictors of Prostate Cancer Tissue Acquisition by an Undirected Core Bone Marrow Biopsy in Metastatic Castration-Resistant Prostate Cancer—A Cancer and Leukemia Group B Study (2005) (26)
- Activity of ketoconazole after taxane‐based chemotherapy in castration‐resistant prostate cancer (2009) (26)
- Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC. (2020) (25)
- Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancer. (2006) (25)
- The Impact of COVID-19 on Clinical Trial Execution at the Dana-Farber Cancer Institute (2020) (25)
- Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies. (2016) (24)
- Impact of prior ketoconazole therapy on response proportion to abiraterone acetate, a 17-alpha hydroxylase C17,20-lyase inhibitor in castration resistant prostate cancer (CRPC) (2008) (23)
- The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancer (2012) (23)
- Dynamic contrast-enhanced magnetic resonance imaging in prostate cancer clinical trials: potential roles and possible pitfalls. (2014) (23)
- (18)F-FDG-PET/CT and (18)F-NaF-PET/CT in men with castrate-resistant prostate cancer. (2015) (23)
- Phase II study of low dose and high dose conjugated estrogen for androgen independent prostate cancer. (2007) (22)
- Efficacy of nilutamide as secondary hormonal therapy in androgen‐independent prostate cancer (2005) (22)
- Clinical predictors of survival in men with castration‐resistant prostate cancer (2013) (22)
- Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer (2021) (22)
- Activity of dutasteride plus ketoconazole in castration-refractory prostate cancer after progression on ketoconazole alone. (2009) (21)
- Clinical factors associated with AR-V7 detection in ARMOR3-SV, a randomized trial of galeterone (Gal) vs enzalutamide (Enz) in men with AR-V7+ metastatic castration-resistant prostate cancer (mCRPC). (2017) (21)
- Phase II multicenter study of abiraterone acetate (AA) plus prednisone therapy in docetaxel-treated castration-resistant prostate cancer (CRPC) patients (pts): Impact of prior ketoconazole (keto). (2009) (21)
- Three-month change in PSA as a surrogate endpoint for mortality in advanced hormone-refractory prostate cancer (HRPC): Data from Southwest Oncology Group Study S9916. (2004) (20)
- Metastatic Castration-Sensitive Prostate Cancer: Optimizing Patient Selection and Treatment. (2018) (19)
- Genomic Resistance Patterns to Second-Generation Androgen Blockade in Paired Tumor Biopsies of Metastatic Castration-Resistant Prostate Cancer (2017) (19)
- Acute renal failure after intravenous anti‐D immune globulin in an adult with immune thrombocytopenic purpura (2003) (19)
- Phase I trial of RAD001 (R) and docetaxel (D) in castration resistant prostate cancer (CRPC) with FDG-PET assessment of RAD001 activity (2008) (19)
- Evidence against T‐cell development in the adult human intestinal mucosa based upon lack of terminal deoxynucleotidyltransferase expression (1996) (18)
- The impact of statin use on the efficacy of abiraterone acetate in patients with castration‐resistant prostate cancer (2017) (18)
- Association of Baseline Corticosteroid with Outcomes in a Multivariate Analysis of the Phase 3 Affirm Study of Enzalutamide (ENZA), An Androgen Receptor Signaling Inhibitor (ARSI) (2012) (18)
- Secondary hormonal therapy in men with castration-resistant prostate cancer. (2011) (17)
- ARMOR2: Galeterone in progressive CRPC patients who have failed oral therapy. (2014) (17)
- Somatic Copy Number Abnormalities and Mutations in PI3K/AKT/mTOR Pathway Have Prognostic Significance for Overall Survival in Platinum Treated Locally Advanced or Metastatic Urothelial Tumors (2015) (17)
- Mechanisms responsible for reduced erythropoiesis during androgen deprivation therapy in men with prostate cancer. (2018) (17)
- Phase II study of three hour, weekly infusion of trabectedin (ET-743) in men with metastatic, androgen-independent prostate carcinoma (AIPC) (2005) (17)
- Abiraterone Acetate: Targeting Persistent Androgen Dependence in Castration-Resistant Prostate Cancer (2013) (17)
- Clinical Outcomes of First‐line Abiraterone Acetate or Enzalutamide for Metastatic Castration‐resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone‐sensitive Prostate Cancer (2017) (16)
- A phase IV, randomized, double-blind, placebo (PBO)-controlled study of continued enzalutamide (ENZA) post prostate-specific antigen (PSA) progression in men with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC). (2017) (15)
- A phase 1b/2 study of CPI-1205, a small molecule inhibitor of EZH2, combined with enzalutamide (E) or abiraterone/prednisone (A/P) in patients with metastatic castration resistant prostate cancer (mCRPC). (2018) (15)
- Docetaxel, estramustine, and short-term androgen withdrawal for patients with biochemical failure after definitive local therapy for prostate cancer. (2001) (14)
- A Molecular Model for Predicting Overall Survival in Patients with Metastatic Clear Cell Renal Carcinoma: Results from CALGB 90206 (Alliance) (2015) (14)
- Antitumor activity of MDV3100 in pre- and post-docetaxel advanced prostate cancer: Long-term follow-up of a phase I/II study. (2011) (14)
- Phosphorylation of androgen receptor serine 81 is associated with its reactivation in castration-resistant prostate cancer. (2018) (14)
- Genetic Effect of Chemotherapy Exposure in Children of Testicular Cancer Survivors (2015) (14)
- Integrative Clinical Genomics of Advanced Prostate Cancer Graphical (2015) (14)
- Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center. (2016) (13)
- Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer. (2005) (13)
- Predictors of duration of abiraterone acetate in men with castration-resistant prostate cancer (2016) (12)
- CD38 in Advanced Prostate Cancers (2021) (12)
- Outcomes Post Neoadjuvant Intense Hormone Therapy and Surgery for Patients with High-Risk Localized Prostate Cancer: Results of a Pooled Analysis of Contemporary Clinical Trials. (2021) (12)
- Treatment of metastatic castration resistant prostate cancer with radium-223: a retrospective study at a US tertiary oncology center (2020) (11)
- Identification of a Synthetic Lethal Relationship between Nucleotide Excision Repair Deficiency and Irofulven Sensitivity in Urothelial Cancer (2020) (11)
- IMAAGEN trial safety and efficacy update: Effect of abiraterone acetate and low-dose prednisone on prostate-specific antigen and radiographic disease progression in patients with nonmetastatic castration-resistant prostate cancer. (2016) (10)
- A PHASE II STUDY OF DOCETAXEL, ESTRAMUSTINE, AND LOW DOSE HYDROCORTISONE IN HORMONE REFRACTORY PROSTATE CANCER: PRELIMINARY RESULTS OF CALGB 9780 (1999) (10)
- Association of tumour microRNA profiling with outcomes in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy (2016) (10)
- CALGB 90203 (Alliance): Radical prostatectomy (RP) with or without neoadjuvant chemohormonal therapy (CHT) in men with clinically localized, high-risk prostate cancer (CLHRPC). (2019) (10)
- Differential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate Cancer (2021) (10)
- Testicular vs adrenal sources of hydroxy-androgens in prostate cancer. (2017) (10)
- Galeterone in men with CRPC: Results in four distinct patient populations from the ARMOR2 study. (2014) (10)
- Phase 1 dose-finding study of cabozantinib (cabo) plus abiraterone (abi) combination therapy in castration resistant prostate cancer (CRPC): An investigator-sponsored study. (2014) (9)
- Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF (2015) (9)
- A phase Ib study of BKM120 combined with abiraterone acetate for castrate-resistant, metastatic prostate cancer. (2014) (9)
- Long-term responders to enzalutamide (ENZA) during the phase III AFFIRM trial: Baseline characteristics and efficacy outcomes. (2013) (9)
- Impact of prior endocrine therapy on radiographic progression-free survival (rPFS) in patients (pts) with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): Results from COU-AA-302. (2014) (9)
- Impact of Pathogenic Germline DNA Damage Repair alterations on Response to Intense Neoadjuvant Androgen Deprivation Therapy in High-risk Localized Prostate Cancer. (2021) (9)
- Prostate cancer: Developing novel approaches to castration‐sensitive disease (2017) (9)
- Enzalutamide for the treatment of prostate cancer: results and implications of the AFFIRM trial. (2014) (8)
- Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and Crizotinib (2020) (8)
- Androgen Receptor Antagonists (2010) (8)
- Androgen Decline and Survival During Docetaxel Therapy in metastatic Castration Resistant Prostate Cancer (mCRPC) (2019) (8)
- Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer. (2013) (8)
- 757OGALETERONE IN 4 PATIENT POPULATIONS OF MEN WITH CRPC: RESULTS FROM ARMOR2. (2014) (8)
- Clinical Outcomes of Chemotherapy Naïve Men with Metastatic Castration Resistant Prostate Cancer and Low Baseline Prostate Specific Antigen Treated with Enzalutamide vs Placebo (2017) (8)
- Androgen receptor modulation optimized for response: Splice variant (ARMOR3-SV)–Randomized, open-label, multicenter, controlled study of galeterone vs enzalutamide in men with metastatic castration-resistant prostate cancer (mCRPC) expressing AR-V7 splice variant. (2015) (8)
- Neoadjuvant androgen pathway suppression prior to prostatectomy. (2012) (8)
- Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer (2015) (8)
- Modeling Androgen Deprivation Therapy–Induced Prostate Cancer Dormancy and Its Clinical Implications (2022) (7)
- Association of B7‐H3 expression with racial ancestry, immune cell density, and androgen receptor activation in prostate cancer (2022) (7)
- Randomized phase II study of olaparib with or without cediranib in men with metastatic castration-resistant prostate cancer (mCRPC). (2020) (7)
- Results of a phase II trial of intense androgen deprivation therapy prior to radical prostatectomy (RP) in men with high-risk localized prostate cancer (PC). (2020) (7)
- A phase Ib open-label, dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with abiraterone or enzalutamide in metastatic castrate-resistant prostate cancer. (2018) (7)
- Biochemical (Prostate-Specific Antigen) Relapse: An Oncologist's Perspective. (2003) (7)
- Efficacy of Therapies After Galeterone in Patients With Castration‐resistant Prostate Cancer (2017) (7)
- Biomarker analysis from a randomized phase II study of olaparib with or without cediranib in men with metastatic castration-resistant prostate cancer (mCRPC). (2021) (7)
- Association of Prostate Cancer SLCO Gene Expression with Gleason Grade and Alterations Following Androgen Deprivation Therapy (2019) (7)
- Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet. (2018) (7)
- Some observations on the reproductive biology of Sminthopsis virginiae (Tarragon)(Marsupialia: Dasyuridae0 (1980) (7)
- Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancer. (2021) (7)
- A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration‐resistant prostate cancer (2018) (6)
- PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase 3 trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients with localized high-risk or locally advanced prostate cancer (PC). (2019) (6)
- Phase II Multicenter Study of Enzalutamide in Metastatic Castration-Resistant Prostate Cancer to Identify Mechanisms Driving Resistance (2021) (6)
- Abstract CT313: An exploratory analysis of efficacy and safety of abiraterone acetate (AA) in black patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy (ctx) (2014) (6)
- Phase II trial of ketoconazole, hydrocortisone, and dutasteride (KHAD) for castration resistant prostate cancer (CRPC) (2008) (6)
- Multiparametric MRI as a Biomarker of Response to Neoadjuvant Therapy for Localized Prostate Cancer-A Pilot Study. (2019) (6)
- Phase II study of low dose (LD) and high dose (HD) premarin in androgen independent prostate cancer (AIPC). (2006) (6)
- COMBAT-CRPC: Concurrent administration of bipolar androgen therapy (BAT) and nivolumab in men with metastatic castration-resistant prostate cancer (mCRPC). (2021) (6)
- Detecting metastatic prostate carcinoma in pelvic lymph nodes following neoadjuvant hormone therapy: the eyes have it! (2016) (6)
- Genetic testing in prostate cancer management: Considerations informing primary care (2022) (6)
- ProSTAR: A phase Ib/II study of CPI-1205, a small molecule inhibitor of EZH2, combined with enzalutamide (E) or abiraterone/prednisone (A/P) in patients with metastatic castration-resistant prostate cancer (mCRPC). (2019) (6)
- Optimizing bone health and minimizing skeletal morbidity in men with prostate cancer. (2013) (5)
- Circulating tumor cells (CTC) and prostate specific antigen (PSA) as response indicator biomarkers in chemotherapy-naïve patients with progressive castration-resistant prostate cancer (CRPC) treated with MDV3100. (2010) (5)
- A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration‐resistant prostate cancer (2018) (5)
- Publisher Correction: The long tail of oncogenic drivers in prostate cancer (2019) (5)
- PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase III trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients with localized high-risk or locally advanced prostate cancer (PC). (2019) (5)
- Biochemical (Prostate-Specific Antigen) Relapse: An Oncologist's Perspective. (2003) (5)
- 4 Activity of galeterone in castrate-resistant prostate cancer (CRPC) with C-terminal AR loss: Results from ARMOR2 (2014) (5)
- Abstract CT094: Phase Ib results of ProSTAR: CPI-1205, EZH2 inhibitor, combined with enzalutamide (E) or abiraterone/prednisone (A/P) in patients with metastatic castration-resistant prostate cancer (mCRPC) (2019) (5)
- Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancer (2021) (4)
- What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021 (2022) (4)
- Results of a phase II trial of neoadjuvant abiraterone + prednisone+ enzalutamide + leuprolide (APEL) versus enzalutamide + leuprolide (EL) for patients with high-risk localized prostate cancer (PC) undergoing radical prostatectomy (RP). (2018) (4)
- LBA-12 CALGB 90203 (ALLIANCE): RADICAL PROSTATECTOMY WITH OR WITHOUT NEOADJUVANT CHEMOHORMONAL THERAPY IN MEN WITH CLINICALLY LOCALIZED, HIGH RISK PROSTATE CANCER (2019) (4)
- Metacure: Multi-arm multimodality therapy for very high risk localized and low volume metastatic prostatic adenocarcinoma. (2019) (4)
- Methylation of SRD5A2 promoter predicts a better outcome for castration-resistant prostate cancer patients undergoing androgen deprivation therapy (2020) (4)
- A phase II study of neoadjuvant chemotherapy with docetaxel and bevacizumab in patients (pts) with high-risk localized prostate cancer: A Prostate Cancer Clinical Trials Consortium trial. (2016) (4)
- A randomized controlled trial of video-education or in-person genetic counseling for men with prostate cancer (ProGen). (2020) (4)
- The ingredients for prostate cancer nomograms: the addition of biomarkers sets the table for future recipes. (2003) (4)
- Adverse events of special interest assessed by review of safety data in enzalutamide castration-resistant prostate cancer (CRPC) trials. (2019) (4)
- 1099 LONG-TERM EFFICACY RESULTS FROM THE PHASE 1-2 STUDY OF MDV3100 IN PRE- AND POST-DOCETAXEL ADVANCED PROSTATE CANCER (2011) (4)
- Has the Time Arrived for Biomarker-Directed Therapy in Castration-Resistant Prostate Cancer? (2015) (4)
- Randomized phase II study evaluating the addition of pembrolizumab to radium-223 in metastatic castration-resistant prostate cancer. (2021) (4)
- A randomized, open-label, phase II study of MDV3100 alone or in combination with leuprolide and dutasteride as neoadjuvant therapy to prostatectomy in intermediate and high-risk prostate cancer. (2012) (4)
- Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer (2021) (4)
- Evolving Role of Prostate-Specific Membrane Antigen-Positron Emission Tomography in Metastatic Hormone-Sensitive Prostate Cancer: More Questions than Answers? (2022) (4)
- Phase II study of Enzalutamide with radiation therapy for intermediate risk prostate cancer: A phase 2 study. (2021) (4)
- Docetaxel plus carboplatin (DC) may have significant activity in hormone refractory prostate cancer (HRPC) patients who have progressed after prior docetaxel-based chemotherapy. (2004) (3)
- Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984 (2022) (3)
- Median time to progression in chemotherapy (chemo)-naive patients with castration-resistant prostate cancer (CRPC) treated with abiraterone acetate and low-dose prednisone (Pred). (2010) (3)
- Secondary hormone therapy for castration-resistant prostate cancer. (2013) (3)
- progression-free survival: Results from ACRIN 6687 (2015) (3)
- 806POutcomes of prechemotherapy (pCRx) abiraterone acetate (AA) or enzalutamide (E) for metastatic castration-resistant prostate cancer (mCRPC) after ADT + Docetaxel (D) or ADT alone for metastatic hormone sensitive prostate cancer (mHSPC) in a multi-institution hospital-based registry (2017) (3)
- Phase II trial of RAD001 (R) and bicalutamide (B) for castration-resistant prostrate cancer (CPRC). (2010) (3)
- Treatment With Galeterone in an Elderly Man With Castration-Resistant Prostate Cancer: A Case Report. (2015) (3)
- A phase 3 study of androgen annihilation in high-risk biochemically relapsed prostate cancer: An Alliance Foundation trial (AFT-19). (2018) (3)
- Genitourinary tumors, prostate (2012) (3)
- Volume of Gleason Pattern 4 Stratifies Risk of Metastasis and Death in Patients with Gleason Score 3+5=8/5+3=8 Positive Prostate Core Biopsies. (2020) (3)
- Neoadjuvant Novel Hormonal Therapy Followed by Prostatectomy versus Up-Front Prostatectomy for High-Risk Prostate Cancer: A Comparative Analysis (2022) (3)
- Post-radical prostatectomy (RP) outcome for patients with high-risk prostate cancer treated with intense neoadjuvant hormone therapy (NHT): Results of a pooled analysis of contemporary clinical trials. (2021) (3)
- Abstract 993: Whole exome sequencing of CTCs as a window into metastatic cancer (2014) (2)
- Quality of life (QOL) and pain in advanced stage prostate cancer: impact of missing data on evaluating palliation in SWOG 9916. (2004) (2)
- Abstract 2905: Clinical and genomic resistance to second generation androgen blockade in paired biopsies of metastatic castration-resistant prostate cancer (2017) (2)
- Docetaxel plus carboplatin (DC) may have significant activity in hormone refractory prostate cancer (HRPC) patients who have progressed after prior docetaxel-based chemotherapy (2004) (2)
- The impact of statin use on abiraterone acetate (AA) treatment duration in patients with castration-resistant prostate cancer (CRPC). (2016) (2)
- Inherited mutations in DNA repair genes in men with metastatic castration-resistant prostate cancer. (2016) (2)
- LBA63 PRESTO: A phase III, open-label study of androgen annihilation in patients (pts) with high-risk biochemically relapsed prostate cancer (AFT-19) (2022) (2)
- Correlation of 18F-fluoride PET response to dasatinib in castration-resistant prostate cancer bone metastases with progression-free survival: Preliminary results from ACRIN 6687. (2013) (2)
- 905 ANTITUMOUR ACTIVITY OF MDV3100 IN A PHASE 1-2 STUDY OF ADVANCED PROSTATE CANCER (2010) (2)
- PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase 3 trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients (pts) with localized or locally advanced high-risk prostate cancer (PC). (2022) (2)
- A phase II study of M6620 in combination with carboplatin compared with docetaxel in combination with carboplatin in metastatic castration-resistant prostate cancer. (2020) (2)
- Analysis of the correlation between endorectal MRI response to neoadjuvant chemotherapy and biochemical recurrence in patients with high-risk localized prostate cancer (2013) (2)
- Effects of dasatinib on prostate cancer bone metastases and normal bone measured by 18F-fluoride PET: Preliminary results from ACRIN 6687 (2013) (2)
- Association between genetic polymorphisms in SLCO1B3 gene and response to ketoconazole (K) in men with castration-resistant prostate cancer (CRPC). (2010) (2)
- Tumor fraction in circulating free DNA as a biomarker of disease dynamics in metastatic prostate cancer. (2018) (2)
- Prior therapy and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC) in a hospital-based database. (2017) (2)
- A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancer (2022) (2)
- Response to olaparib or carboplatin in a real-world cohort of men with DNA damage repair (DDR) deficient metastatic castration-resistant prostate cancer (mCRPC). (2020) (2)
- A phase II multicenter study of neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) chemotherapy with pegfilgrastim support in patients (pts) muscle-invasive urothelial cancer (MIUC): Safety, pathologic, radiologic, and molecular correlates. (2013) (2)
- The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial (2021) (2)
- Prognostic significance of plasma chromogranin A levels in hormone-refractory prostate cancer patients treated on Cancer and Leukemia Group B (CALGB) 9480. (2004) (2)
- Impact of crossover and baseline prognostic factors on overall survival (OS) with abiraterone acetate (AA) in the COU-AA-302 final analysis. (2015) (1)
- Results of a phase II trial of docetaxel (DOC), bevacizumab (BEV), and androgen deprivation therapy (ADT) for biochemical relapse (BCR) after definitive local therapy for prostate cancer (PC). (2014) (1)
- Activity of sequential therapies (txs) in patients (pts) with castration resistant prostate cancer (CRPC) previously treated with galeterone. (2015) (1)
- 647 PHASE 1–2 STUDY OF MDV3100 IN PRE- AND POST-DOCETAXEL ADVANCED PROSTATE CANCER: LONG-TERM EFFICACY RESULTS (2011) (1)
- 580 ANTITUMOR ACTIVITY OF MDV3100 IN A PHASE 1-2 STUDY OF ADVANCED PROSTATE CANCER (2010) (1)
- Pharmacokinetic (PK) analysis of concurrent administration of enzalutamide (enza) and crizotinib (crizo) in patients with metastatic castration resistant prostate cancer (CRPC). (2018) (1)
- Decline in serum androgens and survival in metastatic castration resistant prostate cancer (MCRPC) patients treated with docetaxel and prednisone: Results from CALGB 90401 (alliance) (2018) (1)
- Randomized, open-label, multicenter, controlled study of galeterone vs enzalutamide in men with metastatic castration-resistant prostate cancer (mCRPC) expressing AR-V7 splice variant (ARMOR3-SV). (2016) (1)
- Clinical Outcomes of Chemotherapy-Naïve Men with Metastatic Castration-Resistant Prostate Cancer and Low Baseline PSA Treated with Enzalutamide vs Placebo Running head : Enzalutamide in men with mCRPC and a Low PSA (2017) (1)
- Paradoxical significance of endorectal MRI (erMRI) response to neoadjuvant chemotherapy in patients with high-risk localized prostate cancer (HRLPC). (2013) (1)
- Impact of new systemic therapies on overall survival (OS) of patients (pts) with metastatic castration resistant prostate cancer (mCRPC) in a hospital-based registry. (2018) (1)
- Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. (2022) (1)
- Abstract A17: Abiraterone metabolism and a novel therapeutic strategy for castration resistant prostate cancer (2017) (1)
- Response to docetaxel (D)/carboplatin (C)-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer (HRPC) (2007) (1)
- Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program (2021) (1)
- An investigator-initiated phase I study of crizotinib in combination with enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) before or after progression on docetaxel. (2016) (1)
- Aberrant tumor metabolism to enable glucocorticoid receptor takeover in enzalutamide-resistant prostate cancer. (2017) (1)
- Transgenerational genomic effect of chemotherapy exposure in testicular cancer survivors. (2015) (1)
- Androgens and Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Docetaxel (2020) (1)
- Androgens and Overall Survival in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Docetaxel. (2019) (1)
- 2537 Preliminary findings from PLATO: A two-period, phase 4, randomized, double-blind, placebo-controlled study of continued enzalutamide treatment beyond progression in men with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) (2015) (1)
- Mifepristone (RU-486) in androgen independent prostate cancer. (2006) (1)
- MP70-11 IMPACT OF PRIOR ENDOCRINE THERAPY ON CLINICAL BENEFIT OF ABIRATERONE ACETATE IN PATIENTS WITH CHEMOTHERAPY-NAÏVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: RESULTS FROM COU-AA-302 (2014) (1)
- Genetic counseling processes and outcomes among prostate cancer patients (ProGen). (2019) (1)
- Association of on-treatment plasma HGF levels with overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (INF) +/- bevacizumab (BEV): Results from CALGB 90206 (Alliance). (2017) (1)
- 637P Biochemical response (PSA0) and testosterone (T) recovery in Metacure, a multi-arm multi-modality (MM) therapy (tx) for very high risk localized (HRL) and low volume metastatic (LVM) prostatic adenocarcinoma (2021) (1)
- 861 Impact of prior endocrine therapy on radiographic progression-free survival (rPFS) in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: Results from COU-AA-302 (2014) (1)
- A phase II study of muscadine grape skin extract in men with biochemically recurrent prostate cancer. (2017) (1)
- Clinical Implementation of 177Lu-PSMA-617 in the United States: Lessons Learned and Ongoing Challenges (2023) (1)
- Predicting outcome in metastatic urothelial cancer (UC) receiving docetaxel (DT): miRNA profiling in pre and post therapy. (2015) (1)
- The long tail of significantly mutated genes in prostate cancer. (2017) (1)
- Galeterone in treatment-naïve patients with castration-resistant prostate cancer with C-terminal androgen receptor loss: Results from ARMOR2. (2016) (1)
- A randomized phase II study of androgen deprivation therapy with or without PD0332991 in RB-positive metastatic hormone-sensitive prostate cancer. (2015) (1)
- Association of SLCO transport genes with intraprostatic abiraterone (ABI) levels and pathologic outcomes in men with high-risk localized prostate cancer (PCa). (2015) (1)
- MP44-01 A PROGNOSTIC MODEL FOR OVERALL SURVIVAL IN PATIENTS WITH METASTATIC CLEAR CELL RENAL CARCINOMA: RESULTS FROM CALGB 90206 (ALLIANCE) (2015) (1)
- Case report: responses to cabazitaxel in metastatic castration-resistant prostate cancer after extensive docetaxel treatment. (2011) (1)
- Abstract 1316: Molecular features of complete response to neoadjuvant anti-androgen therapy in high risk localized prostate cancer (2020) (1)
- The long tail of oncogenic drivers in prostate cancer (2018) (1)
- Evaluating a Video-Based, Personalized Webpage in Genitourinary Oncology Clinical Trials: A Phase 2 Randomized Trial (2019) (1)
- MP81-16 METHYLATION OF SRD5A2 PROMOTER PREDICTS A BETTER OUTCOME FOR PATIENTS UNDERGOING ANDROGEN DEPRIVATION THERAPY IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (2019) (0)
- Delayed PSA responses in metastatic castration resistant prostate cancer (mCRPC) patients (pts) treated with sipuleucel-T. (2018) (0)
- Patterns of structural variation define prostate cancer across disease states (2022) (0)
- Resource Integrative Clinical Genomics of Advanced Prostate Cancer (2016) (0)
- Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. (2023) (0)
- A video-based, personalized web page (VBPWP) as a complement to clinical trial (CT) patient management. (2017) (0)
- FORMULA-509: A multicenter randomized trial of post-operative salvage radiotherapy (SRT) and 6 months of GnRH agonist with or without abiraterone acetate/prednisone (AAP) and apalutamide (Apa) post-radical prostatectomy (RP). (2023) (0)
- Abstract CT418: A Phase Ib study of BKM120 combined with abiraterone acetate for castrate-resistant, metastatic prostate cancer (2014) (0)
- Gaining metabolic insight in older men undergoing androgen deprivation therapy for prostate cancer (the ADT & Metabolism Study): Protocol of a longitudinal, observational, cohort study (2023) (0)
- Impact of MRI on outcomes in active surveillance (AS) for localized prostate cancer in a hospital registry. (2020) (0)
- MP37-02 METHYLATION OF SRD5A2 PROMOTER PREDICTS A BETTER OUTCOME FOR PATIENTS UNDERGOING ANDROGEN DEPRIVATION THERAPY IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (2020) (0)
- Differential responses to taxanes and PARP inhibitors in ATM‐ versus BRCA2‐mutated metastatic castrate‐resistant prostate cancer (2022) (0)
- Phase 1 study with expansion cohorts of cabozantinib (C) + abiraterone (A) in metastatic castration resistant prostate cancer (mCRPC): Investigator-sponsored study. (2015) (0)
- A Urologic Oncology Roundtable Discussion: Issues to Consider in Choosing Treatment for Metastatic Castration-Resistant Prostate Cancer (2013) (0)
- Outcomes of prechemotherapy (pCHT) abiraterone (AA) or enzalutamide (E) for metastatic castration-resistant prostate cancer (mCRPC) after androgen deprivation therapy (ADT) + docetaxel (D) or ADT alone for metastatic hormone sensitive prostate cancer (mHSPC) in a hospital-based registry. (2017) (0)
- Association of prostate cancer SLCO gene expression with Gleason grade and alterations following androgen deprivation therapy (2019) (0)
- Androgen decline and survival during docetaxel therapy in metastatic castration resistant prostate cancer (mCRPC) (2019) (0)
- Phase II study of enzalutamide monotherapy with radiation therapy for intermediate risk prostate cancer. (2018) (0)
- Association of serum (SR) and tissue (TX) abiraterone (ABI) levels with intraprostatic steroids and pathologic outcomes in men with high-risk localized prostate cancer (PCa). (2014) (0)
- Follow-up study of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer. (2011) (0)
- Gene-Environment Interactions and Childhood Metabolic Disorders (2012) (0)
- Cancer Therapy : Clinical Phase II Study of Androgen Synthesis Inhibition with Ketoconazole , Hydrocortisone , and Dutasteride in Asymptomatic Castration-Resistant Prostate Cancer (2009) (0)
- Association of emergent neuroendocrine prostate cancer detected by liquid biopsies with survival and treatment resistance. (2023) (0)
- Evaluating a Video-Based, Personalized Webpage in Genitourinary Oncology Clinical Trials: A Phase 2 Randomized Trial (Preprint) (2018) (0)
- Title: Phase 2 multicenter study of enzalutamide in metastatic castration resistant prostate cancer to identify mechanisms driving resistance Authors List: (2021) (0)
- Abstract CN02-03: Circulating tumor cells as biomarkers in the development of the androgen receptor antagonist, MDV3100 (2009) (0)
- Fixed tissue ChIP-seq (FiT-Seq) of archived FFPE clinical bladder cancer (BC) samples to reveal tumor-specific enhancer and super-enhancer profiles. (2016) (0)
- Abstract 3566: The long tail of significantly mutated genes in prostate cancer (2017) (0)
- Fine tuning metabolism of biochemically active abiraterone metabolites to optimize anti-androgen therapy in prostate cancer. (2016) (0)
- A phase Ia/Ib study of talazoparib in combination with tazemetostat in metastatic castration-resistant prostate cancer (mCRPC). (2022) (0)
- Author response: Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide resistant prostate cancer (2016) (0)
- P108 Baseline characteristics and efficacy outcomes of patients with long-term exposure to enzalutamide during the Phase III AFFIRM trial (2013) (0)
- Abstract A024: Prostate cancer neoadjuvant intensive androgen deprivation therapy selects for tumor foci with diverse oncogenic alterations (2018) (0)
- Abstract 4350: Integrative and multiregional molecular analysis of localized, high grade prostate cancer treated with neoadjuvant androgen deprivation treatment (2018) (0)
- Androgen R eceptor M utations i n A ndrogen-Indepen dent Prostate C ancer: C ancer a nd L eukemia G roup B S tudy 9 663 (2003) (0)
- PCN31 REAL-WORLD TREATMENT PATTERNS OF RADIUM-223 IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER RECEIVING CARE AT A US TERTIARY ONCOLOGY CENTER (2020) (0)
- Lack of Effect of Aminoglutethimide and Hydrocortisone Added to High-Dose Bicalutamide for Androgen-Independent Prostate Cancer (2001) (0)
- Clinical implementation of 177Lu-PSMA-617 (LuPSMA) at a major academic center: Initial experiences. (2023) (0)
- 2501 ORAL A randomized, open-label, phase 2 study of enzalutamide as neoadjuvant therapy for patients undergoing prostatectomy for localized prostate cancer (2015) (0)
- Implementation of a prostate cancer‐specific targeted sequencing panel for credentialing of patient‐derived cell lines and genomic characterization of patient samples (2022) (0)
- O10 Enzalutamide, an androgen receptor signaling inhibitor, improves overall survival, time to first skeletal related event and pain (2012) (0)
- Genomic mechanisms of resistance to neoadjuvant leuprolide plus abiraterone in locally advanced prostate cancer. (2017) (0)
- Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade (2017) (0)
- 718 LONG-TERM FOLLOW-UP OF A MULTICENTER PHASE II STUDY OF ABIRATERONE ACETATE (AA) + LOW-DOSE PREDNISONE (P) IN CHEMOTHERAPY-NAIVE MCRPC DEMONSTRATING RADIOGRAPHIC FLARES DISCORDANT WITH SEROLOGIC MEASURES OF RESPONSE (2011) (0)
- Real-world utilization of radium-223 (Ra-223) for the treatment of metastatic castration-resistant prostate cancer (mCRPC): A U.S. tertiary oncology center analysis. (2020) (0)
- Evaluating the frequency and functional consequences of epigenetic mutations on outcome derived from urothelial tumor sequencing in non-muscle invasive bladder cancer (NMIBC). (2015) (0)
- PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness. (2022) (0)
- LBH589 (LBH) and bicalutamide (Bic) in castration-resistant prostate cancer (CRPC) patients (pts) progressing on second line anti-androgen (AA): NYU-08479/PCCTC. (2015) (0)
- Ultrasensitive detection of circulating LINE-1 ORF1p as a specific multi-cancer biomarker (2023) (0)
- Treatment of metastatic castration resistant prostate cancer with radium-223: a retrospective study at a US tertiary oncology center (2020) (0)
- Correction: Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer (2019) (0)
- Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry (2019) (0)
- Abstract 3450: Resistance to P450c17 inhibitors in castration-resistant prostate cancer may result from the DHEA-S depot that remains and can be used by AKR1C3 for intratumoral androgen biosynthesis (2015) (0)
- Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: Results from the phase III AFFIRM study. (2012) (0)
- Association of serum androgen and drug levels with response to abiraterone. (2019) (0)
- A phase II trial of abiraterone acetate (AA) without prednisone in castration resistant prostate cancer (CRPC). (2017) (0)
- Corrigendum to “What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021” [Eur Urol 82(1):6–11] (2022) (0)
- TIME TO BIOCHEMICAL RECURRENCE (BCR) IN PATIENTS WITH LOCALIZED HIGH‐RISK PROSTATE CANCER (PC) TREATED WITH NEOADJUVANT ANDROGEN BLOCKADE (NAB) PRIOR TO RADICAL PROSTATECTOMY (RP): RESULTS OF A POOLED ANALYSIS OF THREE PHASE 2 TRIALS: PD10‐02 (2017) (0)
- Circulating-free DNA (cfDNA) as biomarker of taxane resistance in metastatic castration-resistant prostate cancer (mCRPC). (2020) (0)
- A phase II study of neoadjuvant docetaxel (D) plus bevacizumab (B) in patients (pts) with high-risk localized prostate cancer. (2011) (0)
- Novel Approaches for the Unfavorable Risk Patient (2014) (0)
- Clinical practice patterns of Radium-223 (R223) utilization and variables associated with completion of therapy. (2015) (0)
- Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial). (2023) (0)
- Chemo-hormonal therapy for biochemical progression of prostate cancer. (2006) (0)
- Outcomes with metastasis-directed therapy (MDT) and fixed-duration systemic therapy in oligometastatic hormone-sensitive prostate cancer (omHSPC). (2023) (0)
- Role of miR-21, miR372, and E2F1 as biomarkers predicting outcome in cisplatin-treated bladder cancer patients. (2015) (0)
- Differential responses to taxanes and PARP inhibitors (PARPi) in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer (mCRPC) patients (pts). (2021) (0)
- Baseline characteristics associated with PSA progression-free survival in patients (pts) with high-risk biochemically relapsed prostate cancer: Results from the phase 3 PRESTO study (AFT-19). (2023) (0)
- Impact of SLCO1B3 single nucleotide polymorphisms (SNPs) on outcomes in patients with castration resistant prostate cancer (CRPC) treated with docetaxel. (2018) (0)
- LBA02-11 UPDATED PROGRESSION-FREE SURVIVAL FROM PRESTO: A PHASE 3 RANDOMIZED STUDY OF ANDROGEN ANNIHILATION FOR HIGH-RISK BIOCHEMICALLY RELAPSED PROSTATE CANCER (AFT-19) (2023) (0)
- Abstract PO-100: Association of B7-H3 expression with racial ancestry, immune cell density and AR activation in prostate cancer (2022) (0)
- Androgen decline and outcome in castration resistant prostate cancer (mCRPC) patients treated with docetaxel (Doc), prednisone +/- bevacizumab (B). (2018) (0)
- Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors (2017) (0)
- 665 EFFECT OF NEOADJUVANT ABIRATERONE ACETATE PLUS LEUPROLIDE ACETATE ON PSA, PATHOLOGIC RESPONSE, AND INTRAPROSTATIC/SERUM ANDROGEN LEVELS IN LOCALIZED HIGH-RISK PROSTATE CANCER: RESULTS OF A RANDOMIZED PHASE 2 STUDY (2013) (0)
- 556 Abiraterone acetate improves overall survival in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC): Impact of crossover and baseline prognostic factors in the COU-AA-302 final analysis (2015) (0)
- Circulating Cell-Free DNA as Biomarker of Taxane Resistance in Metastatic Castration-Resistant Prostate Cancer (2021) (0)
- Abstract LB-136: High concordance of whole-exome sequencing of cell-free DNA and matched biopsies enables genomic discovery in metastatic cancer (2016) (0)
- A phase 2 study of berzosertib (M6620) in combination with carboplatin compared with docetaxel in combination with carboplatin in metastatic castration-resistant prostate cancer. (0)
- Addition of Germline Testing to Tumor-Only Sequencing Improves Detection of Pathogenic Germline Variants in Men With Advanced Prostate Cancer. (2022) (0)
- Publisher Correction: The long tail of oncogenic drivers in prostate cancer (2019) (0)
- Serum androgens and survival in metastatic castration resistant prostate cancer (mCRPC) patients treated with docetaxel and prednisone: Results from CALGB 90401 (Alliance). (2017) (0)
- Results of a phase II trial of abiraterone acetate (AA) combined with dutasteride (DUT) for men with metastatic castration resistant prostate cancer (mCRPC). (2014) (0)
- Abstract LB-212: IMAAGEN study biomarker analysis in patients with long term response to abiraterone acetate with prednisone for non-metastatic castrate resistant prostate cancer (2018) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Mary‐ellen Taplin?
Mary‐ellen Taplin is affiliated with the following schools:
